Pelcitoclax (APG-1252) is a potent Bcl-2/Bcl-xl inhibitor with antineoplastic and pro-apoptotic effects. In Vitro APG-1252 changes to the reactive metabolite named APG-1252-M1, which has remarkable antitumor effects in acute myeloid leukemia. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Pelcitoclax (APG-1252; 25-100 mg/kg; i.v.; once a day; for 10 days) treatment inhibits xenograft tumor growth more obviously than the other groups . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: BALB/c athymic nude mice (male, 4-6weeks) injected with N87 cells Dosage: 25 mg/kg, 50 mg/kg, and 100 mg/kg Administration: Intravenous injection; once a day; for 10 days Result: Inhibited xenograft tumor growth more obviously than the other groups. Form:Solid
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
Pelcitoclax
CAS number：1619923-36-2 molecular formula：C57H66ClF4N6O11PS4
overview
compound introduction
Specs
| Chinese alias | 培西托克 | ||
| English alias | APG1252 | APG-1252 | SCHEMBL15872908 | NSC835773 | NSC-835773 | AKOS040755512 | Pelcitoclax | 1619923-36-2 | (R)-3-(1-(3-(4-(N-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-5-methyl-4-(methylsulfonyl)-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yl)phenyl)sulfam | ||
| CAS number | 1619923-36-2 | molecular formula | C57H66ClF4N6O11PS4 |
| molecular weight | 1281.85 g/mol | Exact mass | ≥95% |
| PSA | 275.000 Ų | logp | 7.500 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
